Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedra Bill Likely To Be Subject Of Hearing Within The Next Month

This article was originally published in The Tan Sheet

Executive Summary

A hearing on the "Ephedra Public Protection Act" (HR 1075), which would ban the sale of all ephedrine alkaloid-containing dietary supplements under certain conditions, is expected within the next month

You may also be interested in...



Supplement Bill Increasing FDA Access To Safety Data Planned By Waxman

Reps. Henry Waxman (D-Calif.) and Susan Davis (D-Calif.) are working on legislation "that will give FDA greater access to information to understand if a [dietary supplement] product does pose a health risk and will let FDA protect consumers from unsafe products," Waxman said at a July 23 hearing of the House Energy & Commerce/Oversight & Investigations Subcommittee

Supplement Bill Increasing FDA Access To Safety Data Planned By Waxman

Reps. Henry Waxman (D-Calif.) and Susan Davis (D-Calif.) are working on legislation "that will give FDA greater access to information to understand if a [dietary supplement] product does pose a health risk and will let FDA protect consumers from unsafe products," Waxman said at a July 23 hearing of the House Energy & Commerce/Oversight & Investigations Subcommittee

Supplement Bill Increasing FDA Access To Safety Data Planned By Waxman

Reps. Henry Waxman (D-Calif.) and Susan Davis (D-Calif.) are working on legislation "that will give FDA greater access to information to understand if a [dietary supplement] product does pose a health risk and will let FDA protect consumers from unsafe products," Waxman said at a July 23 hearing of the House Energy & Commerce/Oversight & Investigations Subcommittee

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095215

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel